Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04218708 · ClinicalTrials.gov registry record · NA
Electronic Cigarettes as a Harm Reduction Strategy Among People Living With HIV/AIDS
A NA study, sponsored by NYU Langone Health.
- Completed
- Registry status
- NA
- Development phase
- 64
- Enrollment target
NCT04218708: Completed NA study, sponsored by NYU Langone Health.
NCT04218708 is a NA study that has completed, run by NYU Langone Health. The registered enrollment target is 64 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04218708, a NA study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 64 participants
- Enrollment target
Study Summary
This is a research study to understand and determine the effectiveness of electronic cigarettes versus nicotine replacement therapy in adults who smoke and also live with HIV/AIDS in effort to reduce cigarette smoking.
Primary Outcome
In the e-cigarette arm, participants will be encouraged to substitute SREC (15 mg/ml nicotine in tobacco flavor) for CC in order to reduce nicotine withdrawal symptoms. Smoking reduction will be measured by a combination of self-report, text message data and changes in CO and saliva cotinine between baseline and end of treatment.
Interventions
- BEHAVIORAL Counseling
- OTHER Nicotine patch and gum
- BEHAVIORAL Minnesota Nicotine Withdrawal Scale (MNWS)
- BEHAVIORAL ASSIST (the Alcohol, Smoking and Substance Involvement Screening)
- OTHER NIDA Standardized Research E-cigarettes (SREC)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2021-06-17 |
| Est. Completion | 2024-03-08 |
| Phase | NA |
What the finished NCT04218708 record still lists
NCT04218708 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 5 interventions - of which Counseling is the first listed.
NCT04218708 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04218708 about?
NCT04218708 is a clinical study titled "Electronic Cigarettes as a Harm Reduction Strategy Among People Living With HIV/AIDS". This is a research study to understand and determine the effectiveness of electronic cigarettes versus nicotine replacement therapy in adults who smoke and also live with HIV/AIDS in effort to reduce cigarette smoking.
What is the current status of trial NCT04218708?
This trial is currently completed. It is a NA study. The enrollment target is 64 participants. The study started on 2021-06-17. Estimated completion is 2024-03-08.
What interventions are being tested in trial NCT04218708?
The interventions under investigation include: Counseling (BEHAVIORAL), Nicotine patch and gum (OTHER), Minnesota Nicotine Withdrawal Scale (MNWS) (BEHAVIORAL), ASSIST (the Alcohol, Smoking and Substance Involvement Screening) (BEHAVIORAL), NIDA Standardized Research E-cigarettes (SREC) (OTHER).
Who is sponsoring clinical trial NCT04218708?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04218708's enrollment target sits among peer trials
64 1147th of 2000 higher than 844 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI